Amylin (AMLN) hasn't had the best run of late.
There have been safety concerns about the drug Byetta (largely overblown), competition concerns from rival drugs (not-so-overblown), and worries about the timing, efficacy, and competitive profile of the long-acting version of Byetta. Making matters worse, Amylin management hasn't exactly conducted themselves in the most up-front and transparent matter, burying notice of a potentially significant delay in the LAR drug in an 8-K.
I don't like companies that put out press releases to trumpet success, but try to bury setbacks in SEC filings that they hope no one will read.
In any case, word today from Lilly/Amylin/Alkermes suggests that the can use a current ongoing study in place of a separate bioequivalence study. That's good news, as this company clearly needs to get the LAR drug on the market as quickly as possible...
(full disclosure - I'm long Amylin, though some days I wonder why...)
No comments:
Post a Comment